Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness

AIDS. 2010 Sep 10;24(14):2201-9. doi: 10.1097/QAD.0b013e32833d2132.

Abstract

Background: Previous research has demonstrated an increase in carotid intima-media thickness (cIMT) in HIV-infected individuals compared to controls. However, the reason for this increased level of subclinical vascular disease is unknown.

Objective: To identify HIV-related risk factors for increased cIMT.

Methods: We evaluated the relationship between HIV-related characteristics (including markers of HIV disease severity and use of antiretroviral therapy) and cIMT measurements in the internal/bulb and common carotid regions among 538 HIV-infected participants from the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). We used Bayesian model averaging to estimate the posterior probability of candidate HIV and non-HIV-related risk factors being true predictors of increased cIMT. Variables with a posterior probability of more than 50% were used to develop a selected regression model for each of the anatomic regions.

Results: For common cIMT, the Bayesian model selection process identified age, African-American race, and systolic and diastolic blood pressure with probability more than 95%, HDL cholesterol with probability 85% and Hispanic ethnicity with probability 51%. Among the HIV-related factors included in the analysis, only tenofovir use was selected (51% probability). In the selected model, duration of tenofovir use was associated with lower common cIMT (-0.0094 mm/year of use; 95% confidence interval: -0.0177 to -0.0010). For internal cIMT, no HIV-related risk factors were above the 50% posterior probability threshold.

Conclusion: We observed an inverse association between duration of tenofovir use and common carotid cIMT. Whether this association is causal or due to confounding by indication needs further investigation.

Trial registration: ClinicalTrials.gov NCT00331448.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Antiretroviral Therapy, Highly Active
  • Atherosclerosis / chemically induced*
  • Atherosclerosis / pathology
  • Atherosclerosis / virology
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV-1*
  • Humans
  • Male
  • Middle Aged
  • Organophosphonates / administration & dosage
  • Organophosphonates / adverse effects*
  • Risk Factors
  • Tenofovir
  • Tunica Intima / pathology*
  • Tunica Media / pathology*

Substances

  • Organophosphonates
  • Tenofovir
  • Adenine

Associated data

  • ClinicalTrials.gov/NCT00331448

Grants and funding